Keratoconus, often referred to as “KC”, is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge and optical irregularity of the cornea. This causes “static” in your vision and can result in significant vision impairment.1
What is Cross-Linking?
A minimally invasive method for the treatment of Keratoconus
Cross-linking is an alternative to corneal transplantation to retain vision. If diagnosed with progressive keratoconus, FDA-approved cross-linking is a treatment option that is clinically proven to limit the progression of the sight-threatening disease.
Corneal collagen cross-linking is a non-invasive procedure combining the use of ultra-violet light with the KXL® System and Photrexa® riboflavin drug formulations.
Corneal collagen cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus, a sight-threatening eye disease. Historically, as many as 1 in 5 patients with progressive keratoconus have required a corneal transplant, with more than half needing multiple transplants within 20 years.
1 Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology 2006;113(9):1633-8.
2 Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens 2014;40(6):382-9.
FDA Approved CXL Procedure – Clark Chang, OD from Avedro on Vimeo.